XENON PHARMACEUTICALS INC. Other Research and Development Expense
XENON PHARMACEUTICALS INC. (XENE) reported Other Research and Development Expense of $4.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherResearchAndDevelopmentExpense · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. other research and development expense for the quarter ending 2026-06-30 was $4.64M, a 78.54% increase year-over-year.
- XENON PHARMACEUTICALS INC. other research and development expense for the quarter ending 2026-03-31 was $4.20M, a 22.66% increase year-over-year.
- XENON PHARMACEUTICALS INC. other research and development expense for the quarter ending 2025-12-31 was $3.77M, a 161.30% increase year-over-year.
- XENON PHARMACEUTICALS INC. other research and development expense for the quarter ending 2025-09-30 was $2.73M, a 24.55% decline year-over-year.
- XENON PHARMACEUTICALS INC. other research and development expense for fiscal 2025 was $12.52M, a 11.46% increase from fiscal 2024.
- XENON PHARMACEUTICALS INC. other research and development expense for fiscal 2024 was $11.23M, a 17.49% increase from fiscal 2023.
- XENON PHARMACEUTICALS INC. other research and development expense for fiscal 2023 was $9.56M, a 31.43% increase from fiscal 2022.
- XENON PHARMACEUTICALS INC. other research and development expense for fiscal 2022 was $7.27M.
| Period end | Other Research and Development Expense 3 month | Other Research and Development Expense 6 month | Other Research and Development Expense 9 month | Other Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.64M 10-Q · filed 2026-08-06 | $8.84M 10-Q · filed 2026-08-06 | $12.61M derived: sum of 3 quarters · filed 2026-08-06 | $15.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.20M 10-Q · filed 2026-05-07 | $7.97M derived: sum of 2 quarters · filed 2026-05-07 | $10.70M derived: sum of 3 quarters · filed 2026-05-07 | $13.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.49M derived: sum of 2 quarters · filed 2026-02-26 | $9.09M derived: sum of 3 quarters · filed 2026-08-06 | $12.52M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.73M 10-Q · filed 2025-11-03 | $5.33M derived: sum of 2 quarters · filed 2026-08-06 | $8.75M 10-Q · filed 2025-11-03 | $10.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.60M 10-Q · filed 2026-08-06 | $6.03M 10-Q · filed 2026-08-06 | $7.47M derived: sum of 3 quarters · filed 2026-08-06 | $11.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.42M 10-Q · filed 2026-05-07 | $4.87M derived: sum of 2 quarters · filed 2026-05-07 | $8.48M derived: sum of 3 quarters · filed 2026-05-07 | $11.64M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.05M derived: sum of 2 quarters · filed 2026-02-26 | $8.22M derived: sum of 3 quarters · filed 2026-02-26 | $11.23M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.61M 10-Q · filed 2025-11-03 | $6.78M derived: sum of 2 quarters · filed 2025-11-03 | $9.79M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $3.16M 10-Q · filed 2025-08-11 | $6.18M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $3.01M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $9.56M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $7.27M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |